Binah Capital Group, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig Michael Gould
- Full Time Employees
- 150
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 80 State Street Albany NY United States of America 12207
- IPO Date
- Mar 27, 2024
- CIK
- 0001953984
- Website
- wentworthms.com
- Similar Companies
- Business
- Binah Capital Group, Inc. Binah Capital Group, Inc. (NASDAQ:BCG) operates as a financial services holding company that owns and manages a network of independent broker-dealers and wealth management firms, providing independent financial advisors with execution, compliance, technology, and back-office support services. The company offers access to stock, bond, exchange-traded fund, and options execution services; research, compliance, supervision, accounting, and related support for advisors; mutual funds and insurance products including fixed and variable annuities; and alternative investments such as non-traded real estate investment trusts and unit trusts; advisory fees; securities commissions; and commissions from variable annuities and other insurance products. Binah Capital Group, Inc. focuses on consolidating fragmented independent broker-dealers to achieve economies of scale in a technology-driven regulatory environment, serving financial advisors and their clients primarily in the United States through subsidiaries including Wentworth Management Services LLC, Purshe Kaplan Sterling Investments, Inc., and Cabot Lodge Securities, LLC; founded in 2016, the company maintains headquarters at 80 State Street in Albany, New York, and employs approximately 150 people under CEO Craig Gould. In recent developments, Binah Capital Group, Inc. plays a key role in major industry consolidations, earning recognition in Financial Planning's "Top IBD Moves and M&A Deals of 2024" list for involvement in four significant transactions featuring affiliates with Americana Partners, Merit Financial Advisors, Wentworth Management Services, and Perigon Wealth Management, underscoring its strategy to facilitate partnerships, scale operations, and expand market presence amid sector consolidation. The company reports revenue growth, with total revenues reaching $90.4 million for the six months ended June 30, 2025, up from prior periods, alongside assets under management increases and ongoing issuances of Series A redeemable convertible preferred stock and Series B convertible preferred stock to support expansion.
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In 'Durable Consumer Goods' By WirtschaftsWoche And Boston Consulting Group
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Binah Capital Group Reports Results for First Quarter of 2026
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
Binah Capital Group (NASDAQ:BCG) Shares Down 9% – Here’s What Happened
Binah Capital Group Reports Results for Fourth Quarter and Full Year 2025
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Binah Capital Group (NASDAQ:BCG) versus Barings Participation Investors (NYSE:MPV) Financial Comparison
Federated Hermes (NYSE:FHI) vs. Binah Capital Group (NASDAQ:BCG) Head to Head Review
Contrasting Silvercrest Asset Management Group (NASDAQ:SAMG) & Binah Capital Group (NASDAQ:BCG)